Compare NUTX & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | AVLN |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2009 | 2026 |
| Metric | NUTX | AVLN |
|---|---|---|
| Price | $191.49 | $38.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $252.50 | N/A |
| AVG Volume (30 Days) | 120.9K | ★ 175.8K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.93 | N/A |
| EPS | ★ 15.87 | N/A |
| Revenue | ★ $875,257,000.00 | N/A |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $77.21 | $24.90 |
| 52 Week High | $204.00 | $39.99 |
| Indicator | NUTX | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 71.28 |
| Support Level | $146.07 | $26.38 |
| Resistance Level | $195.52 | $39.99 |
| Average True Range (ATR) | 13.84 | 2.24 |
| MACD | 3.57 | 1.01 |
| Stochastic Oscillator | 79.05 | 89.68 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.